IP Library Granted Patent US 9,090,643
Granted Patent B2
US 9,090,643 · App. 13/716,569 · Granted Jul 28, 2015

Enhanced immunogenicity of tumor associated antigens by addition of alphagal epitopes

Inventors: Mario R. Mautino (Ankeny, IA); Nicholas N. Vahanian (Polk City, IA); Won-Bin Young (Pittsburgh, PA); Gabriela Rossi (Ankeny, IA); Charles J. Link (Clive, IA); Firoz Jaipuri (Ames, IA)
Assignee: NEWLINK GENETICS CORPORATION
C07H5/04A61K39/0011A61K39/39C07H15/00C07H15/04A61K31/70A61K2039/55511
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,090,643
App. No.
13/716,569
Granted
Jul 28, 2015
Kind
B2
Abstract

The invention relates to methods and compositions for causing the selective targeting and killing of tumor cells. The present invention describes prophylactic or therapeutic cancer vaccines based on purified TAA proteins or TAA-derived synthetic peptides altered by chemical, enzymatic or chemo-enzymatic methods to introduce αGal epitopes or αGal glycomimetic epitopes, in order to allow for enhanced opsonization of the antigen by natural anti-αGal antibodies to stimulate TAA capture and presentation, thereby inducing a humoral and cellular immune response to the TAA expressed by a tumor. The animal's immune system thus is stimulated to produce tumor specific cytotoxic cells and antibodies which will attack and kill tumor cells present in the animal.

Claims (4)

1. A composition of chemical structure B—N(CH 3 )—O—R 1 —COOR 2 , wherein B is a monosaccharide, disaccharide, tetrasaccharide, or pentasaccharide, wherein R 1 is any linear alkyl group of 1 to 30 carbon atoms, wherein one or more of said carbon atoms in said alkyl group can be substituted by O, S, or N and wherein one or more hydrogens can be substituted by hydroxyl carbonyl, alkyl, sulphydryl, or amino groups, and wherein R 2 is an amino or sulphydryl reacting group.

2. The composition of claim 1 , wherein R 2 is succinimide or maleimide.

3. The composition of claim 1 , wherein substitutions of the R 1 alkyl chain create an ester group.

4. A composition of chemical structure B—N(CH 3 )—O—R 1 —COOR 2 , wherein B is a monosaccharide, disaccharide, tetrasaccharide, or pentasaccharide, wherein R 1 is any linear alkyl group of 1 to 30 carbon atoms, wherein one or more of said carbon atoms in said alkyl group can be substituted by O, S, or N and wherein one or more hydrogens can be substituted by hydroxyl carbonyl, alkyl, sulphydryl, or amino groups, and wherein R 2 is succinimide or maleimide.

Assignments (2)
CHANGE OF NAME Recorded Jun 17, 2020
From: NEWLINK GENETICS CORPORATION
To: LUMOS PHARMA, INC.
Reel/Frame 052965/0558 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 8, 2013
From: MAUTINO, MARIO R.; VAHANIAN, NICHOLAS N.; YOUNG, WON-BIN; ROSSI, GABRIELA; LINK, CHARLES J., JR.; JAIPURI, FIROZ
To: NEWLINK GENETICS CORPORATION
Reel/Frame 030374/0132 →
Continuity (4)
Continuation 13173692 · Jun 30, 2011
Continuation 11977203 · Oct 24, 2007
Provisional Application 60862840 · Oct 25, 2006
Related Publication 20130178613A1 · Jul 11, 2013